Edition:
India

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

51.01USD
18 Jun 2019
Change (% chg)

-- (--)
Prev Close
$51.01
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
198,818
52-wk High
$60.98
52-wk Low
$36.19

Latest Key Developments (Source: Significant Developments)

Esperion Therapeutics Qtrly Diluted Earnings Per Share $3.07
Wednesday, 8 May 2019 

May 8 (Reuters) - Esperion Therapeutics Inc ::ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FIRST QUARTER FINANCIAL RESULTS.Q1 REVENUE $145.4 MILLION.Q1 REVENUE ESTIMATE $65.9 MILLION -- REFINITIV IBES DATA.EXPECTS FULL-YEAR 2019 NET CASH USED IN OPERATIONS TO BE $25 MILLION TO $35 MILLION.QTRLY BASIC EARNINGS PER SHARE $3.26.QTRLY DILUTED EARNINGS PER SHARE $3.07.Q1 EARNINGS PER SHARE VIEW $0.74, REVENUE VIEW $65.9 MILLION -- REFINITIV IBES DATA.  Full Article

Esperion Announces U.S. FDA Acceptance Of New Drug Applications
Monday, 6 May 2019 

May 5 (Reuters) - Esperion Therapeutics Inc ::ESPERION ANNOUNCES U.S. FDA ACCEPTANCE OF NEW DRUG APPLICATIONS (NDAS) FOR BOTH BEMPEDOIC ACID AND THE BEMPEDOIC ACID / EZETIMIBE COMBINATION TABLET FOR FILING AND REGULATORY REVIEW.SAYS PDUFA GOAL DATE FOR COMPLETION OF BEMPEDOIC ACID NDA REVIEW IS SET FOR FEBRUARY 21, 2020.FDA ALSO COMMUNICATED THERE IS NO CURRENT PLAN TO HOLD AN ADVISORY COMMITTEE MEETING TO DISCUSS APPLICATIONS.PDUFA GOAL DATE FOR COMPLETION OF BEMPEDOIC ACID / EZETIMIBE COMBINATION TABLET NDA REVIEW IS SET FOR FEBRUARY 26, 2020.  Full Article

Esperion Announces Agreement with Daiichi Sankyo Europe to Commercialize Bempedoic Acid in Europe
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Esperion Therapeutics Inc ::ESPERION ANNOUNCES AGREEMENT WITH DAIICHI SANKYO EUROPE (DSE) TO COMMERCIALIZE BEMPEDOIC ACID IN EUROPE.ESPERION TO RECEIVE $300 MILLION IN UPFRONT AND NEAR-TERM MILESTONES.ESPERION TO RECEIVE $300 MILLION IN UPFRONT AND NEAR-TERM MILESTONES.TO RECEIVE UP TO $900 MILLION IN TOTAL MILESTONES.FDA AND EMA LDL-C APPROVAL DECISIONS ARE EXPECTED DURING FIRST HALF OF 2020.ESPERION THERAPEUTICS -GLOBAL CARDIOVASCULAR OUTCOMES TRIAL OF BEMPEDOIC ACID, IS ONGOING, CARDIOVASCULAR RISK REDUCTION RESULTS EXPECTED DURING 2022.WILL GRANT DAIICHI SANKYO EUROPE EXCLUSIVE COMMERCIALIZATION RIGHTS TO COMMERCIALIZE BEMPEDOIC ACID IN EUROPE.ESPERION WILL RECEIVE AN UPFRONT CASH PAYMENT OF $150 MILLION AS WELL AS $150 MILLION UPON FIRST COMMERCIAL SALES IN TERRITORY.DAIICHI SANKYO EUROPE WILL BE RESPONSIBLE FOR COMMERCIALIZATION IN TERRITORIES.WILL RECEIVE SUBSTANTIAL TIERED ROYALTIES ON NET TERRITORY SALES.ENTERED INTO A LICENSING AGREEMENT WITH DAIICHI SANKYO EUROPE (DSE).  Full Article

Esperion Therapeutics Inc Says Effective Dec 20, 2018, Mark Glickman Was Determined To Be An 'Executive Officer' Of Co
Saturday, 22 Dec 2018 

Dec 21 (Reuters) - Esperion Therapeutics Inc ::ESPERION THERAPEUTICS INC - EFFECTIVE DEC 20, 2018, MARK GLICKMAN WAS DETERMINED TO BE AN 'EXECUTIVE OFFICER' OF CO - SEC FILING.ESPERION THERAPEUTICS INC - EFFECTIVE DEC 20, 2018, NARENDRA LALWANI CEASED TO BE AN 'EXECUTIVE OFFICER' OF CO.  Full Article

Esperion Therapeutics Reports Qtrly Loss Per Share $1.86
Friday, 2 Nov 2018 

Nov 1 (Reuters) - Esperion Therapeutics Inc ::ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.ESPERION THERAPEUTICS - REMAIN ON-TRACK TO SUBMIT NDAS FOR BOTH BEMPEDOIC ACID AND BEMPEDOIC ACID / EZETIMIBE COMBINATION PILL DURING Q1 2019.QTRLY LOSS PER SHARE $1.86.Q3 EARNINGS PER SHARE VIEW $-1.63 -- THOMSON REUTERS I/B/E/S.  Full Article

Esperion Announces Third Pivotal Phase 3 Study Of Bempedoic Acid Meets Primary Endpoint
Wednesday, 23 May 2018 

May 23 (Reuters) - Esperion Therapeutics Inc ::ESPERION ANNOUNCES THIRD PIVOTAL PHASE 3 STUDY OF BEMPEDOIC ACID MEETS PRIMARY ENDPOINT.ESPERION - STUDY 3 ACHIEVES ADDITIONAL 26% LDL-C LOWERING ON BACKGROUND OF MAXIMALLY TOLERATED LDL-C LOWERING THERAPY IN PATIENTS CONSIDERED STATIN INTOLERANT.ESPERION THERAPEUTICS INC - CUMULATIVE PHASE 2 / PHASE 3 DEMONSTRATES BROAD EFFICACY AS WELL AS SAFETY AND TOLERABILITY.  Full Article

Esperion Therapeutics Says Bempedoic Acid Observed To Be Safe & Well-Tolerated In Phase 3 Study
Wednesday, 7 Mar 2018 

March 7 (Reuters) - Esperion Therapeutics Inc ::ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM FIRST PIVOTAL PHASE 3 STUDY OF BEMPEDOIC ACID.ESPERION THERAPEUTICS SAYS PHASE 3 STUDY OF BEMPEDOIC ACID MET PRIMARY ENDPOINT WITH 28% LOW DENSITY LIPOPROTEIN CHOLESTEROL LOWERING.ESPERION THERAPEUTICS SAYS BEMPEDOIC ACID OBSERVED TO BE SAFE AND WELL-TOLERATED IN THE PHASE 3 STUDY.  Full Article

Esperion Reports Qtrly Loss Per Share $1.44
Tuesday, 20 Feb 2018 

Feb 20 (Reuters) - Esperion Therapeutics Inc ::ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.ESPERION THERAPEUTICS INC - EXPECTS FULL-YEAR 2018 NET CASH USED IN OPERATING ACTIVITIES TO BE APPROXIMATELY $135 TO $145 MILLION.ESPERION THERAPEUTICS INC - EXPECTS CASH AND CASH EQUIVALENTS AND INVESTMENT SECURITIES TO BE ABOUT $130 TO $140 MILLION AT DEC 31, 2018.ESPERION THERAPEUTICS INC - QTRLY LOSS PER SHARE $1.44.  Full Article

Esperion Therapeutics Q3 loss per share $1.86‍​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Esperion Therapeutics Inc :Esperion provides bempedoic acid franchise development program updates; reports third quarter 2017 financial results.Expects full-year 2017 net cash used in operating activities to be approximately $135 million​.Expects cash and cash equivalents and investment securities to be approximately $272 million at December 31.Estimates cash resources are sufficient to fund operations through Q1 2020​.Qtrly loss per share $1.86‍​.Q3 earnings per share view $-1.78 -- Thomson Reuters I/B/E/S.  Full Article

Esperion announces initiation of pivotal late stage study for bempedoic acid
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Esperion Therapeutics Inc :Esperion announces initiation of pivotal late stage study for the bempedoic acid / ezetimibe combination pill.Esperion Therapeutics - ‍NDA submission for LDL-C lowering indication for bempedoic acid / ezetimibe combination pill expected by Q1 2019​.Esperion Therapeutics Inc - ‍top-line results expected by q4 of 2018 for bempedoic acid / ezetimibe combination pill​.  Full Article